[1] Para R, Romero F, George G, et al. Metabolic reprogramming as a driver of fibroblast activation in pulmonary fibrosis[J]. Am J Med Sci, 2019,357(5):394-398. [2] Chapman H A. Epithelial-mesenchymal interactions in pulmonary fibrosis[J]. Annu Rev Physiol, 2011,73:413-435. [3] Kim K K, Kugler M C, Wolters P J, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix[J]. Proc Natl Acad Sci U S A, 2006,103(35):13180-13185. [4] Sugimoto H, LeBleu V S, Bosukonda D, et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis[J]. Nat Med, 2012,18(3):396-404. [5] Wang Y, Liang D, Zhu Z, et al. Bone morphogenetic protein-7 prevented epithelial-mesenchymal transition in RLE-6TN cells[J]. Toxicol Res (Camb), 2016,5(3):931-937. [6] Wang Y, Yang G, Zhu Z, et al. Effect of bone morphogenic protein-7 on the expression of epithelial-mesenchymal transition markers in silicosis model[J]. Exp Mol Pathol, 2015,98(3):393-402. [7] Tanjore H, Xu X C, Polosukhin V V, et al. Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis[J]. Am J Respir Crit Care Med, 2009,180(7):657-665. [8] Richeldi L, Collard H R, Jones M G. Idiopathic pulmonary fibrosis[J]. Lancet, 2017,389(10082):1941-1952. [9] Raghu G, Collard H R, Egan J J, et al. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management[J]. Am J Respir Crit Care Med, 2011,183(6):788-824. [10] Duck A, Pigram L, Errhalt P, et al. IPF care:a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe[J]. Adv Ther, 2015,32(2):87-107. [11] Thannickal V J. Mechanisms of pulmonary fibrosis:role of activated myofibroblasts and NADPH oxidase[J]. Fibrogenesis Tissue Repair, 2012,5(Suppl 1):S23. [12] Rennard S I, Bitterman P B, Crystal R G. Response of the lower respiratory tract to injury. Mechanisms of repair of the parenchymal cells of the alveolar wall[J]. Chest, 1983,84(6):735-739. [13] Fletcher S, Jones M G, Spinks K, et al. The safety of new drug treatments for idiopathic pulmonary fibrosis[J]. Expert Opin Drug Saf, 2016,15(11):1483-1489. [14] Iwano M, Plieth D, Danoff T M, et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis[J]. J Clin Invest, 2002,110(3):341-350. [15] Zeisberg M, Yang C, Martino M, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition[J]. J Biol Chem, 2007,282(32):23337-23347. [16] Foroutan M, Cursons J, Hediyeh-Zadeh S, et al. A transcriptional program for detecting TGF beta-induced EMT in cancer[J]. Mol Cancer Res, 2017,15(5):619-631. [17] Leung C C, Yu I T, Chen W. Silicosis[J]. Lancet, 2012,379(9830):2008-2018. [18] Lovisa S, LeBleu V S, Tampe B, et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis[J]. Nat Med, 2015,21(9):998-1009. [19] Sun J, Li Q, Lian X, et al. MicroRNA-29b mediates lung mesenchymal-epithelial transition and prevents lung fibrosis in the silicosis model[J]. Mol Ther Nucleic Acids, 2019,14:20-31. [20] Feng H, Lu J J, Wang Y, et al. Osthole inhibited TGF beta-induced epithelial-mesenchymal transition (EMT) by suppressing NF-kappaB mediated Snail activation in lung cancer A549 cells[J]. Cell Adh Migr, 2017,11(5-6):464-475. [21] Hu Y B, Li F F, Deng Z H, et al. Transcriptional factor snail mediates epithelial-mesenchymal transition in human bronchial epithelial cells induced by silica[J]. Biomed Environ Sci, 2015,28(7):544-548. |